… heart failure, b all-cause mortality, c cardiovascular mortality, … heart failure, all-cause mortality,
cardiovascular mortality, and major adverse cardiovascular events between dapagliflozin …

… dapagliflozin on the incidence of ventricular arrhythmias and sudden death in patients with
heart failure … death remains the principal cause of mortality in ambulatory patients with HFrEF, …

… of dapagliflozin on morbidity and mortality in … heart failure (HF) in patients who had HFrEF
with and without type 2 diabetes. In this study, we explored whether the effect of dapagliflozin …

… Failure) showed that dapagliflozin added to other guideline-recommended therapies … of
mortality and heart failure hospitalization and improved symptoms in patients with heart failure …

… Treatment effects of dapagliflozin on all-cause mortality were not statistically significant (HR: …
heart failure event) between dapagliflozin and placebo arms. DELIVER = Dapagliflozin …

… eligible for dapagliflozin had better clinical outcomes with respect to all-cause mortality and
… ratio for all-cause mortality or readmission in patients eligible for dapagliflozin was 0.82 (95…

… worsening heart failure (HF) in patients with heart failure and … dapagliflozin on the predefined
secondary end point of total … dapagliflozin on morbidity and mortality in patients with heart …

… in patients with heart failure and … of dapagliflozin, which lowers systolic blood pressure
(SBP),according to baseline SBP in Dapagliflozin and Prevention of Adverse Outcomes in Heart …

… for heart failure in the dapagliflozin group than in the placebo group was due to a lower rate
of hospitalization for heart failure in the dapagliflozin … have limited a mortality benefit. Overall …

… A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin
on morbidity and mortality in patients with heart failure and reduced left ventricular ejection …